niftify.in

The Economic Times

Panacea, Sanofi settle patent litigation over hexavalent vaccine

Panacea Biotec has settled a patent infringement case with Sanofi Healthcare India over a hexavalent vaccine. Sanofi will not launch its Shan6 vaccine in India and will withdraw its opposition to Panacea's patent. Panacea will forgo claims for damages. The Delhi High Court disposed of the suit on September 13, 2024.

The Economic Times

Panacea Biotec, Sanofi settle patent infringement suit

Panacea Biotec has settled a patent infringement dispute with Sanofi Healthcare India regarding its fully liquid hexavalent vaccine, EasySix. Sanofi agreed not to launch its Shan6 vaccine in India and will withdraw oppositions against Panacea's patent amendment application. The Delhi High Court disposed of the suit on September 13, 2024.

The Economic Times

Panacea Biotec gets $20 million loan from US government for hexavalent vaccine capacity expansion

Panacea Biotec has secured a $20 million long-term loan from the US International Development Finance Corporation to expand its hexavalent vaccine production. This funding will help the company meet global demand for childhood immunization, supplying vaccines to UN agencies. The hexavalent vaccine, EasySix, protects against six diseases and is expected to see significant demand growth by 2030.

The Economic Times

DFC commits USD 20 mn long-term loan to Panacea Biotec

US International Development Finance Corporation has committed a long-term loan of up to USD 20 million to Panacea Biotec. The funds will help expand the manufacturing capacity for drug substance antigens used in its hexavalent vaccine EasySix, aimed at meeting future demand from UN agencies and public health organisations.

CNBC TV18

Panacea Biotec jumps as Karnataka declares dengue epidemic

The company revealed on August 14 that it has begun Phase-3 clinical trials for its Tetravalent Dengue Candidate Vaccine-DengiALL in India, following approval from the Drug Controller General of India (DCGI).

Business Standard

Shashijit Infraprojects Ltd leads losers in 'B' group

Suraj Ltd, Capital India Finance Ltd, Ruchi Infrastructure Ltd and Panacea Biotec Ltd are among the other losers in the BSE's 'B' group today, 29 August 2024.

The Economic Times

Stock market update: Stocks that hit 52-week highs on NSE in today's trade

CESC Ventures, Uma Exports, Oriental Trimex, Panacea Biotec and Jet Freight Logistic, hit their fresh 52-week highs during the day.

The Economic Times

In a medical breakthrough, first phase-3 dengue vaccine trial begins in India

India started its inaugural phase 3 clinical trial for the DengiAll dengue vaccine, developed by Panacea Biotec. The trial will include 10,335 healthy adults at 19 sites across various states, supported by the Indian Council of Medical Research. Health Minister J P Nadda called it a significant step in India's ongoing battle against dengue.

The Economic Times

First-ever phase-three clinical trial for dengue vaccine initiated in India

The Indian Council of Medical Research (ICMR) and Panacea Biotec have launched the first phase three clinical trial for an indigenous dengue vaccine, DengiAll. Conducted across 19 sites in 18 states, this trial aims to involve over 10,335 healthy adults. The vaccine, developed by Panacea Biotec, follows promising results from earlier trials and is a significant step in India's fight against dengue. With no licensed vaccine currently available in India, this initiative highlights the country’s progress in vaccine research and its commitment to improving public health.